SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

Начало・Списък с акции・Genfit

Genfit

Затворен

СекторЗдравеопазване

8.305 -2.12

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.25

Максимум

8.41

Ключови измерители
By Trading Economics
Приходи	-10M
Продажби	36M
Марж на печалбата	-28.017
Служители	188
EBITDA	955K

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+80.3% upside

Дивиденти
By Dow Jones
Следващи печалби	2.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	422M
Предишно отваряне	10.43
Предишно затваряне	8.305

Настроения в новините

By Acuity

34%

66%

104 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

3.566 / 4.12 Подкрепа & съпротива

Genfit Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.03.2026 г., 17:33 ч. UTC

Значими събития в новините

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27.03.2026 г., 17:00 ч. UTC

Значими събития в новините

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27.03.2026 г., 16:03 ч. UTC

Значими събития в новините

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27.03.2026 г., 14:50 ч. UTC

Значими двигатели на пазара

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27.03.2026 г., 14:37 ч. UTC

Придобивния, сливания и поглъщания

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27.03.2026 г., 14:29 ч. UTC

Значими събития в новините

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27.03.2026 г., 14:16 ч. UTC

Значими събития в новините

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 19:16 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27.03.2026 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27.03.2026 г., 19:04 ч. UTC

Пазарно говорене

Gold Rises But Can't Finish the Week Positive -- Market Talk

27.03.2026 г., 19:03 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 19:02 ч. UTC

Пазарно говорене

Значими събития в новините

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27.03.2026 г., 18:12 ч. UTC

Пазарно говорене

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27.03.2026 г., 17:36 ч. UTC

Значими събития в новините

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27.03.2026 г., 17:34 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27.03.2026 г., 17:29 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27.03.2026 г., 16:38 ч. UTC

Пазарно говорене

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27.03.2026 г., 16:32 ч. UTC

Пазарно говорене

Значими събития в новините

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27.03.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 15:43 ч. UTC

Пазарно говорене

Значими събития в новините

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27.03.2026 г., 15:00 ч. UTC

Значими събития в новините

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27.03.2026 г., 15:00 ч. UTC

Значими събития в новините

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27.03.2026 г., 15:00 ч. UTC

Значими събития в новините

Fed's Barkin Says Iran War Raising Economic Uncertainty

27.03.2026 г., 14:36 ч. UTC

Пазарно говорене

Значими събития в новините

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27.03.2026 г., 14:26 ч. UTC

Пазарно говорене

Значими събития в новините

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27.03.2026 г., 14:14 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 14:14 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Genfit Прогноза

Ценова цел

By TipRanks

80.3% нагоре

12-месечна прогноза

Среден 15.001 EUR 80.3%

Висок 15 EUR

Нисък 15 EUR

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Genfit през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Genfit през последните 3 месеца.

Техническа оценка

By Trading Central

3.566 / 4.12Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Настроение

By Acuity

104 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.